Astrazeneca (AZN) Non-Current Assets (2009 - 2026)

Astrazeneca (AZN) has reported Non-Current Assets for 18 consecutive years, with $84.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets rose 5.35% year-over-year to $84.4 billion; the TTM figure through Mar 2026 stood at $84.4 billion (up 5.35% YoY), while the FY2025 annual figure was $85.4 billion, up 21.47% from the prior year.
• Non-Current Assets came in at $84.4 billion for Q1 2026 at Astrazeneca, down from $85.4 billion in the prior quarter.
• The five-year high for Non-Current Assets was $85.4 billion in Q4 2025, with the low at $68.9 billion in Q4 2022.
• Average Non-Current Assets over 5 years is $77.1 billion, with a median of $76.7 billion recorded in 2024.
• The largest YoY upside for Non-Current Assets was 112.7% in 2022 against a maximum downside of 8.16% in 2022.
• Year by year, Non-Current Assets stood at $68.9 billion in 2022, then advanced by 0.15% to $69.0 billion in 2023, then grew by 1.88% to $70.3 billion in 2024, then gained by 21.47% to $85.4 billion in 2025, then declined by 1.11% to $84.4 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $84.4 billion, $85.4 billion, and $84.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.